国家心血管病中心(National Center for Cardiovascular Diseases)是中央机构编制委员会办公室于2009年11月3日批复成立的公益性事业单位,隶属国家卫生健康委员会。国家心血管病中心位于北京市门头沟永定镇冯村西里。根据《国家卫生健康委关于印发国家心血管病中心主要职责、内设机构和人员编制规定的通知》(国卫人发〔2019〕27号),中心为公益二类事业单位。
BACKGROUND:The novel thin-strut sirolimus-eluting iron bioresorbable scaffold (IBS) demonstrated safety and efficacy in a nonrandomized first-in-human study. OBJECTIVES:The objective of this study was to compare the IBS with contemporary metallic cobalt chromium everolimus-eluting stents (CoCr-EES) in patients with coronary artery disease. METHODS:IRONMAN-II was a prospective, multicenter, single-blinded, noninferiority randomized trial across 36 centers in China. Eligible patients had myocardial ischemia and 1 or 2 de novo target lesions. Patients were randomly assigned (1:1) to IBS or CoCr-EES, with allocation masked. Optical coherence tomography (OCT) was performed in the first 25 participant pairs. Clinical follow-up was scheduled at 1, 6, and 12 months, and annually to 5 years, with angiographic and OCT follow-up at 2 years. The primary endpoint was 2-year angiographic in-segment late lumen loss (LLL). Powered secondary endpoints included target vessel quantitative flow ratio (QFR) and OCT-derived cross-sectional mean flow area. Other secondary endpoints included target lesion failure (cardiac death, target vessel myocardial infarction [MI], or ischemia-driven target vessel revascularization), the patient-oriented composite endpoint (all-cause death, MI, or any revascularization), their individual components, and device thrombosis. RESULTS:Between March 10 and December 13, 2022, 518 patients were randomized to IBS (n = 259) or CoCr-EES (n = 259). At 2 years, lesion-level in-segment LLL was 0.28 (0.52) mm with IBS and 0.23 (0.43) mm with CoCr-EES (difference: 0.08 mm; 95% CI: -0.02 to 0.18; Pnoninferiority = 0.03). Mean QFR was 0.90 (0.13) with IBS and 0.92 (0.09) with CoCr-EES (difference: -0.02; 95% CI: -0.04 to 0; Pnoninferiority = 0.05). Mean OCT flow area was 6.92 (3.48) mm2 with IBS and 6.64 (2.44) mm2 with CoCr-EES (difference: 0.27; 95% CI: -0.09 to 0.63; Pnoninferiority < 0.0001). Two-year target lesion failure occurred in 7.4% of IBS patients and 5.4% of CoCr-EES patients (HR: 1.37; 95% CI: 0.69-2.73; P = 0.37). No significant between-group differences in the rates of patient-oriented composite endpoint, death, or MI were present between the 2 groups. No scaffold thromboses occurred in the IBS group, whereas 1 stent thrombosis occurred with CoCr-EES. Binary restenosis and revascularization rates were higher with IBS, however, most such events were non-ischemia-driven. CONCLUSIONS:In IRONMAN-II, the sirolimus-eluting IBS was noninferior to CoCr-EES for 2-year in-segment LLL, QFR, and OCT-derived flow area. Clinical event rates were also comparable between groups although non-ischemia-driven revascularization rates were higher after IBS. Longer-term follow-up is necessary to demonstrate whether late benefits are realized after complete IBS resorption. (A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease; NCT05206084).
In patients with stable coronary artery disease (CAD), the long-term benefits of revascularization over medical therapy remain unclear. In the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 trial, patients with hemodynamically significant stenoses (fractional flow reserve (FFR) ≤ 0.80) were randomized to receive FFR-guided percutaneous coronary intervention (PCI) plus medical therapy (n = 447) or medical therapy alone (n = 441). At 5 years, FFR-guided PCI reduced the risk of the primary composite outcome of time to death, myocardial infarction or urgent revascularization, largely because of fewer urgent revascularizations. We now report the long-term clinical outcomes from this trial. Sixteen hospitals, contributing 748 randomized patients (161 women, 21.5 NCT06159231 . In a long-term follow-up of the FAME 2 trial, fractional flow reserve-guided percutaneous coronary intervention plus medical therapy in patients with stable coronary artery disease reduced cardiovascular events compared to medical therapy alone, primarily due to a decrease in urgent revascularization events.
BACKGROUND:The multicenter, randomized, sham-controlled FAVOR III China trial (Comparison of Quantitative Flow Ratio-Guided and Angiography-Guided Percutaneous Intervention in Patients with Coronary Artery Disease) demonstrated that quantitative flow ratio (QFR)-guided percutaneous coronary intervention (PCI) resulted in better outcomes compared with angiographic guidance at 1-year and 2-year follow-up. Whether these benefits are sustained over long-term follow-up remains uncertain. OBJECTIVES:The purpose of this study was to evaluate the long-term effectiveness and safety of a QFR-guided PCI strategy compared with angiography-guided PCI at 5 years. METHODS:Patients with at least 1 angiographically intermediate coronary lesion (50%-90% diameter stenosis) in a vessel ≥2.5 mm diameter were randomized to a QFR-guided (PCI performed only if QFR ≤0.80) or angiography-guided strategy. The primary endpoint was major adverse cardiac events (a composite of all-cause death, myocardial infarction, or ischemia-driven revascularization) at 1 year; 5-year outcomes data are reported herein. RESULTS:At 5 years, major adverse cardiac events composite was lower with QFR guidance than with angiography guidance (17.5% vs 21.1%; HR: 0.80; 95% CI: 0.69-0.92; P = 0.002), driven by fewer myocardial infarctions (5.8% vs 9.0%; HR: 0.63; 95% CI: 0.49-0.80; P < 0.0001) and ischemia-driven revascularizations (9.6% vs 12.0%; HR: 0.78; 95% CI: 0.64-0.95; P = 0.02) in the QFR-guided group. All-cause death did not differ between groups. Landmark analysis showed that the benefit of QFR guidance accrued predominantly within the first 2 years (8.5% vs 12.5%; HR: 0.66; 95% CI: 0.54-0.81; P < 0.0001), with similar outcomes between 2 and 5 years (10.2% vs 11.2%; HR: 0.90; 95% CI: 0.73-1.11; P = 0.32; P for interaction = 0.001). CONCLUSIONS:Compared with angiography guidance, QFR-guided strategy improved 5-year clinical outcomes, with benefits primarily achieved within the first 2 years. (The FAVOR III China Study; NCT03656848).
Abstract Background Heart failure with preserved ejection fraction (HFpEF) is increasingly recognised as a heterogeneous syndrome, yet identifying rare, high-risk clinical phenotypes within broad cohorts remains a challenge. Crucially, it remains unclear whether the biomarkers defining these data-driven subtypes are the same ones that drive their long-term prognostic risk in routine clinical cohorts. Aims We sought to operationalise a high-risk thyroid-endothelial phenotype using AutoML-optimised classifiers and to examine if the biological drivers of phenotype membership are concordant with those of adverse outcomes, with implications for risk stratification. Methods In 1,754 retrospective HFpEF patients, we performed hypothesis-driven Ward's clustering of standardised TSH, free triiodothyronine (FT3), and Big endothelin-1 (BigET) to evaluate the thyroid-endothelial axis independently of NT-proBNP. XGBoost and TabNet classifiers, refined via evolutionary AutoML and 5-fold cross-validation, were trained for phenotype reproduction and outcome discrimination. SHapley Additive exPlanations (SHAP) were used to quantify biomarker contributions. Prognostic independence was assessed using multivariable Cox models adjusted for NT-proBNP, eGFR, and clinical covariates. Given the low prevalence of P2, outcome models were intentionally parsimonious. Results We identified a high-risk subgroup (Phenotype 2 [P2], 7.9%) characterised by a low-FT3/high-BigET signature. P2 patients had significantly higher event rates than Phenotype 1 (46.0% vs 32.6%; 57/124 vs 479/1470; P<0.001). After adjusting for NT-proBNP and eGFR, P2 remained independently associated with adverse outcomes (HR 1.659; 95% CI 1.242-2.217; P<0.001; bootstrap 95% CI 1.268-2.212). While classifiers replicated P2 assignment with high accuracy (Out-of-fold AUC: 0.999), outcome discrimination was expectedly modest (AUC 0.680). SHAP analysis revealed a clear biological dissociation: BigET was the dominant contributor to phenotype definition (mean |SHAP| 4.09), whereas FT3 emerged as the primary contributor to prognostic risk (0.43). Conclusions Interpretable machine learning enables the identification of niche HFpEF subtypes while revealing a "defined-by-endothelium, risk-driven-by-thyroid" pattern. This statistical dissociation suggests that markers defining specific HFpEF clusters may not align with their prognostic drivers, requiring a more nuanced approach to risk stratification. The phenotype is deployable using routine blood tests, enabling potential early risk enrichment beyond natriuretic peptide–based assessment, though external validation remains essential.Fig1 Out-of-fold ROC phenotype vs outcomeFig2 SHAP dissociation definition vs risk
Abstract Background Despite the recognised co-occurrence of malnutrition and systemic inflammation in heart failure with preserved ejection fraction (HFpEF), the incremental prognostic value of a simple nutritional score beyond NT-proBNP—and the clinical relevance of inflammation-driven effect modification—has not been established. Aims We evaluated the prognostic utility of the Controlling Nutritional Status (CONUT) score in HFpEF, tested effect modification by inflammation (hsCRP), compared CONUT with PNI and GNRI, and quantified incremental utility using NRI and decision-curve analysis (DCA). Methods From a retrospective single-centre HFpEF registry (n=2,190), 1,061 patients with complete NT-proBNP and hsCRP were analysed. CONUT (albumin, cholesterol, lymphocyte count) was evaluated alongside PNI and GNRI. The primary composite comprised all-cause mortality, cardiovascular death, HF hospitalisation, or sudden cardiac death. Cox models adjusted for age, sex, BMI, eGFR, LVEF, log(NT-proBNP), comorbidities and therapy, including a pre-specified CONUT×hsCRP interaction (≥3 vs <3 mg/L). Incremental utility was assessed by ΔC-index, category-free NRI, and 1-year DCA. Results Over a median follow-up of 2.8 years, 400 composite events and 284 all-cause deaths occurred. CONUT was independently associated with the composite outcome (adjusted HR 1.129 per point; 95% CI 1.084–1.175; P<0.001). Discrimination gains were modest (ΔC-index 0.0080), but reclassification improved (category-free NRI 2.3%, bootstrap 95% CI 0.9–4.0%; P=0.002), outperforming PNI and GNRI. Clinical+CONUT increased net benefit on 1-year DCA across 10–30% thresholds (30%: 0.85 fewer missed events/100). Interaction was significant (P=0.014): HR per point 1.153 with hsCRP ≥3 mg/L vs 1.082 with hsCRP <3 mg/L. Conclusions CONUT provides incremental prognostic and clinical utility beyond NT-proBNP, particularly with elevated hsCRP, defining a malnutrition–inflammation phenotype that may inform triage and nutritional evaluation. As a retrospective single-centre study without external validation, prospective confirmation is required.Inflammation amplifies CONUT risk in HFpEF